Oxford BioMedica (OTCMKTS:OXBDF) Shares Up 15% – What’s Next?

Shares of Oxford BioMedica (OTCMKTS:OXBDF) shot up 15% during trading on Tuesday. The stock traded as high as $7.65 and last traded at $7.65. Approximately 100 shares were traded during mid-day trading, a decline of 98% from the average session volume of 5,962 shares. The stock had previously closed at $6.65.

Wall Street Analyst Weigh In

Separately, Zacks Research raised Oxford BioMedica to a “hold” rating in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Oxford BioMedica has an average rating of “Hold”.

Oxford BioMedica Stock Up 6.8%

The firm’s 50-day moving average is $6.94 and its two-hundred day moving average is $7.67.

About Oxford BioMedica

Oxford BioMedica plc is a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company works with biotechnology and pharmaceutical customers to develop, manufacture and test viral vectors and other biological materials used in advanced therapies.

Its capabilities include process and analytical development, clinical and commercial manufacturing, quality control, regulatory support and technology transfer. Oxford BioMedica has particular expertise in lentiviral vectors, which are used to deliver genetic material into cells, and also provides services involving adeno-associated virus and other viral-vector platforms.

Founded in 1995 and headquartered in Oxford, England, the company serves customers internationally across the pharmaceutical and biotechnology industries.